Results 291 to 297 of about 29,210 (297)

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Lancet Oncology, The, 2015
Janet Valdez, Georg Aue, Nakhle S Saba
exaly  

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

Lancet Oncology, The, 2016
Jeffrey A Jones, Anthony R Mato, Peter Hillmen   +2 more
exaly  

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

Lancet Oncology, The, 2014
Jan A Burger, Michael J Keating, William G Wierda   +2 more
exaly  

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy

Nature Communications, 2017
Dan A Landau, Clare Sun, Daniel Rosebrock   +2 more
exaly  

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia

Journal of Clinical Oncology, 2018
Steven P Treon, Joshua N Gustine, Guang Yang   +2 more
exaly  

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Journal of Clinical Oncology, 2013
Ranjana H Advani, Sonali M Smith, Nathan Fowler   +2 more
exaly  

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

Lancet Oncology, The, 2016
David A Santos, L Jeffrey Medeiros, Richard E Champlin   +2 more
exaly